What question did this study set out to answer?

The study aims to evaluate the prognostic value of tumor mutational burden in patients with relapsed/refractory large B-cell lymphoma receiving CAR-T therapy.

December 8, 2025Blood

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

SRSandeep RajMemorial Sloan Kettering Cancer Center AGAaron H. GillmorMemorial Sloan Kettering Cancer Center ARAllison L. RichardsMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Observational findings link high tumor mutational burden with worse progression-free survival in large B-cell lymphoma, suggesting immune signaling impacts CAR-T efficacy.

Key Points

The study aims to evaluate the prognostic value of tumor mutational burden in patients with relapsed/refractory large B-cell lymphoma receiving CAR-T therapy.
Analyzed tumor biopsies from 119 patients with relapsed/refractory large B-cell lymphoma treated with CAR-T.
Measured tumor mutational burden using whole exome sequencing and targeted next-generation sequencing.
Evaluated associations with relapse and progression using Fine-Gray regression and Cox regression for survival analysis.
Higher tumor mutational burden associated with increased risk of relapse and poor outcomes.
Patients in the top tumor mutational burden quartile showed over twofold higher risk of adverse outcomes: progression-free survival risk ratio 2.30, overall survival risk ratio 2.21.
Transcriptomic analysis revealed reduced expression of inflammatory pathways in high tumor mutational burden patients.

Cite This Study

Raj et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc8d https://doi.org/10.1182/blood-2025-565

View Full Paper

Ask AI

Bookmark

Implication

Observational findings link high tumor mutational burden with worse progression-free survival in large B-cell lymphoma, suggesting immune signaling impacts CAR-T efficacy.

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider